Seattle Genetics, Inc. is a biotechnology Company focused on developing and commercializing antibody-based therapies for the treatment of cancer. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, its pipeline includes six clinical-stage ADC programs consisting of SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and multiple preclinical programs including SEA-CD40, a non-fucosylated anti-CD40 antibody utilizing a immuno-oncology technology. Its technologies include antibody-drug conjugate (ADC) technology and Seattle Genetics sugar-engineered antibody (SEA) technology. The Company’s pipeline of monoclonal antibody-based product candidates is based on its ADC technology.